|Bid||130.39 x 100|
|Ask||130.43 x 200|
|Day's Range||127.45 - 130.91|
|52 Week Range||97.70 - 143.22|
|PE Ratio (TTM)||48.38|
|Earnings Date||Apr 23, 2018 - Apr 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||146.37|
Stocks that moved substantially or traded heavily Wednesday: Comcast Corp., up 91 cents to $34.26 The cable company had a solid first quarter and offered to buy U.K. broadcaster Sky for $30 billion. Texas ...
Motivated by a goal to create meaning in his work, Edwards Lifesciences[ticker symb=EW] CEO Mike Mussallem pushed boundaries to follow his passion for helping people live their best lives. In the process, Mussallem and his team have transformed Edwards into the global leader in patient-focused innovations for structural heart disease, as well as critical care and surgical monitoring. Mussallem believes...
Premarket trading turned mixed on Wednesday as Boeing, Twitter and Cree gained, Alphabet got an upgrade and Comcast bid $31 billion for Britain's Sky.
Japan is the company’s highest growth region outside the United States. Therapy adoption continues to be the major factor driving Edwards’ THVT segment sales in 1Q18. For more on related developments, read Recent Developments at Edwards Lifesciences.
Edwards Lifesciences Corp (NYSE:EW) and Illumina, Inc. (NASDAQ:ILMN) reported their quarterly earnings results after hours Tuesday, while Tesla Inc (NASDAQ:TSLA) finds itself in hot waters over a contract dispute. Edward Lifesciences reported its latest quarterly results after hours yesterday. The company announced that the first-quarter global sales of its heart valves, a metric that marks the company’s most important growth driver, increased 2.3% year-over-year to $551.5 million.
Edwards Lifesciences Corp's first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc. The company's shares fell as much as 8.1 percent in after-market trading as sales of its premium non-invasive device, used to replace diseased aortic valves without open-heart surgery, is its biggest growth driver. "Procedure growth in Europe was double digits this quarter, while our growth was lower due to a year-over-year shift in share to our largest competitor," Chief Executive Officer Michael A. Mussallem said on a call with analysts.
Edwards Lifesciences Corp. shares dropped in late trading Tuesday after the company provided a disappointing forecast. The company reported first-quarter earnings of 96 cents a share on sales of $894.8 ...
Here’s a list of all the top-rated growth stocks that have just been added to the IBD 50, IBD Big Cap 20, Sector Leaders, Stock Spotlight and IPO leaders.
For the first quarter, Edwards reported $937.5 million in adjusted sales and adjusted profit of $1.22 per share.
On a per-share basis, the Irvine, California-based company said it had net income of 96 cents. Earnings, adjusted for non-recurring costs, were $1.22 per share. The results beat Wall Street expectations. ...
Medical device maker Edwards Lifesciences Corp reported a 1.3 percent rise in first-quarter revenue on Tuesday on higher demand for transcatheter heart valves, its biggest business. The company's net profit ...
IRVINE, Calif. , April 24, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...
NEW YORK, NY / ACCESSWIRE / April 24, 2018 / Edwards Lifesciences Corporation (NYSE: EW ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 24, 2018 at 5:00 PM Eastern ...
Over the last month, BSX stock has registered a rise of ~4.2%. The company came out on top in patent infringement litigation against Edwards Lifesciences (EW), for which a hearing is scheduled in May at the German Court of Appeal. On April 16, Boston Scientific announced its acquisition of Nvision Medical Corporation for a cash payment of $150 million and an additional milestone-based payment over the next four years amounting to $125 million.
In 1Q18, Boston Scientific (BSX) is expected to report adjusted EPS (earnings per share) of $0.32, representing YoY (year-over-year) growth of ~8.7%. The company reported adjusted EPS of $0.34 in fiscal 4Q17, and it had registered YoY growth of ~14.8%. The adjusted EPS were in line with Wall Street expectations.
On April 25, Boston Scientific (BSX) plans to announce its 1Q18 earnings results—the quarter that ended on March 31. According to Wall Street analysts’ estimates, the company’s 1Q18 revenues are expected to come in at $2.34 billion, representing YoY (year-over-year) growth of ~8.4%.
Edwards Lifesciences (EW) will announce its 1Q18 earnings results for the quarter ended March 31, 2018, on April 24. The company is a leader in the TAVR (transcatheter aortic valve replacement) market space and manufactures the market-leading Sapien family of valves. The company reported robust 4Q17 and fiscal 2017 results on February 1, 2018, which triggered a 7% of stock price rise.
The company has been growing aggressively through strategic acquisitions. This month, the company announced the acquisition of Nvision Medical Corporation in the area of women’s health and Securus Medical in the area of electrophysiology. The company is slated to announce its 1Q18 earnings results on April 25. In this article, let’s discuss the company’s Wall Street recommendations and target prices for the next 12 months.
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.